DRAK2 polyclonal antibody, anti-human, mouse, rat

Background:
DAP (death associated protein) kinase and ZIP kinase are members of a novel protein kinase family, the members of which have the capacity to mediate apoptosis through their catalytic activities. DAP kinase contains a "death domain" and has been shown to mediate gamma interferon-induced apoptosis. The introduction of DAP kinase into highly metastatic carcinoma clones lacking DAP kinase expression was shown to result in the suppression of metastasis, thus linking suppression of apoptosis to metastasis. ZIP kinase contains a leucine zipper domain, which is necessary for homodimerization and for interaction with other leucine zipper proteins. ZIP kinase dimerizes with ATF-4, an ATF/CREB transcription factor family member that contains a leucine zipper. DRAK1 (DAP kinase-related apoptosis-inducing protein kinase 1) and DRAK2 are DAP kinase related proteins. DRAK1 and DRAK2 are localized to the nucleus, and overexpression of both DRAK proteins in NIH/3T3 cells induces morphological changes associated with apoptosis.

Research Area: Cell Biology

Synonyms: STK17B, DRAK2, Serine/threonine-protein kinase 17B, DAP kinase-related apoptosis-inducing protein kinase 2

Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration: 1 mg/ml

Storage:
-20°C for 1 year